GlassScriptPhysician profile
Elizabeth K Mann
NPI 1790712099
$4,467.22
in general payments reported to CMS, 2019-2025
34 companies · $590 in 2025
The $590 reported for 2025 was more than what 84% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $574 · 2020: $271 · 2021: $868 · 2022: $793 · 2023: $783 · 2024: $588 · 2025: $590.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,896 · Education: $64.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,896.17 |
| Education | $64.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $528.75 | 2019-2024 | |
| Mayne Pharma Commercial LLC | $479.41 | 2021-2025 | |
| Aspira Women'S Health INC | $446.55 | 2020-2024 | Ova1 |
| Daiichi Sankyo INC. | $368.50 | 2019-2025 | Injectafer |
| Astellas Pharma US INC | $306.03 | 2021-2025 | Veozah |
| Amgen INC. | $302.92 | 2019-2022 | |
| Shield Therapeutics INC | $217.57 | 2023-2025 | Accrufer |
| Pfizer INC. | $207.27 | 2019-2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $194.29 | 2019-2025 | |
| Duchesnay USA Incorporated | $162.49 | 2019 | |
| Novo Nordisk INC | $158.35 | 2020-2023 | Wegovy |
| Exeltis, USA INC. | $136.69 | 2019-2025 | Slynd |
| Hologic Sales and Service, LLC | $107.21 | 2022-2025 | Acessa Provu System, Omni Hysteroscope |
| Organon LLC | $101.34 | 2022-2024 | |
| Therapeuticsmd, INC. | $100.20 | 2019-2022 |
Show all 34 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Agile Therapeutics, INC. | $94.72 | 2021-2022 | |
| Biogen, INC. | $70.01 | 2024 | Zurzuvae |
| Merck Sharp & Dohme LLC | $51.73 | 2023 | Gardasil 9 |
| Avion Pharmaceuticals | $50.83 | 2019-2022 | |
| Coopersurgical, INC. | $44.56 | 2021-2024 | Paragard T 380a |
| Mylan Pharmaceuticals INC. | $42.05 | 2019-2022 | |
| Currax Pharmaceuticals LLC | $33.76 | 2020 | |
| Scynexis, INC. | $31.20 | 2022 | |
| Bausch Health US, LLC | $28.38 | 2021 | |
| Si-Bone, INC. | $27.72 | 2025 | |
| Davol INC. | $26.15 | 2023 | Arista Ah Flexitip |
| Evofem Biosciences, INC. | $25.94 | 2021 | |
| Amag Pharmaceuticals, INC. | $23.79 | 2019 | |
| Roche Diagnostics Corporation | $23.70 | 2020 | |
| Becton, Dickinson and Company | $20.52 | 2025 | Hemosphere |
| Glaxosmithkline, LLC. | $15.47 | 2021 | |
| Medtronic, INC. | $14.04 | 2023 | Truclear |
| Boston Scientific Corporation | $12.74 | 2019 | |
| Lupin INC. | $12.34 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Elizabeth Mann listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.